Anvisa Approves Medicine to Treat Schistosomiasis in Children
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
Anvisa approved the registration of Farmanguinhos Arpraziquantel, a medicine to treat schistosomiasis in children from 3 months to 6 years, a group until then outside the pediatric indication. At least 253.7 million people needed preventive treatment against the disease in the world in 2024, according to the WHO.
Arpraziquantel is indicated for children aged 3 to 6 years and can destroy the worms that cause the disease
The disease is acquired by contact with fresh water that contains caramuli infected by worms causing
Tribuna Online
Agence Nacional de Vigilância Sanitária (Anvisa) Photo: Marcelo Camargo/Agência Brasil The Agence Nacional de Vigilância Sanitária (Anvisa) approved on Wednesday (30) the registration of the drug Farmanguinhos Arpraziquantel, indicated for the treatment of schistosomosis caused by the parasite Schistosome mansoni or Schistosome haematobium in children from 3 months to 6 years.The resolution was published in the Official Journal of the Union.In a…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
